Largest multi ~ In a groundbreaking announcement, Medtronic (NYSE: MDT) has revealed that their Expand URO Investigational Device Exemption (IDE) clinical study has successfully met both primary safety and effectiveness endpoints. This study, which is the largest of its kind for robotic-assisted urologic surgery, included 137 patients who underwent procedures using the Hugo™ robotic-assisted surgery (RAS) system.

The Hugo™ RAS system, developed by Medtronic, is a modular and multi-quadrant platform designed specifically for soft-tissue robotic-assisted surgery. The results of this study have been described by the American Urologic Association (AUA) as a "practice-changing, paradigm-shifting (P2) clinical trial in urology". These findings were presented at the AUA annual meeting in Las Vegas by Dr. Michael R. Abern, the national principal investigator of the study and a urologic surgeon at Duke University Hospital in Durham, N.C.

More on nvtip.com

• Twitter's Buzzing! What's the Deal with PhotoG, the AI Everyone's Talking About?
• New WHO Mental Health Guidelines Condemn Coercive Psychiatry
• Keenan's Caring Konnections, LLC
• Blackridge Partners Ltd. examines Q1 earnings that fall short of market projections
• Celebrate Children's Day in Tochigi City!

Dr. Abern expressed his excitement about the study's outcomes, stating that "the Hugo RAS system met the safety and effectiveness endpoints and produced results consistent with published literature for robotic-assisted urologic surgery." As the first surgeon to perform a case in this clinical study, he emphasized how rewarding it is to see such positive results from this rigorous and significant research in the field of robotic surgery.

This achievement marks a major milestone for Medtronic and their commitment to advancing healthcare technology. With these promising results from their Expand URO IDE clinical study, Medtronic continues to solidify its position as a global leader in healthcare technology.

---

Show All News | Report Violation